- Scleritis, a serious inflammatory eye disease, is increasingly recognized as a critical area in ophthalmology due to its association with systemic autoimmune disorders and potential for severe vision impairment if left untreated
- The rising incidence of autoimmune conditions such as rheumatoid arthritis and lupus, along with enhanced awareness and diagnostic capabilities in ophthalmic care, is fueling demand for effective scleritis treatments
- North America dominated the scleritis market with the largest revenue share of 41.7% in 2024, supported by advanced healthcare infrastructure, high awareness among patients, and the availability of innovative biologic therapies and immunosuppressants. The U.S. particularly leads in diagnosis and treatment volumes due to its large pool of specialists and access to advanced medications
- Asia-Pacific is expected to be the fastest-growing region in the scleritis market, projected to grow at a CAGR of 8.9% from 2025 to 2032, driven by increasing healthcare expenditures, a growing patient population, and expanding access to specialty ophthalmic care in countries such as India, China, and Japan
- Medication segment dominated the scleritis market with a market share of 77.6% in 2024, fueled by the widespread use of corticosteroids, immunosuppressants, and NSAIDs in scleritis management
